Cargando…

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Lung cancer is an extremely heterogeneous disease, and its treatment remains one of the most challenging tasks in medicine. Few existing laboratory lung cancer models can faithfully recapitulate the diversity of the disease and predict therapy response. Here, we establish 12 patient-derived organoid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhichao, Qian, Youhui, Li, Wujiao, Liu, Lisa, Yu, Lei, Liu, Xia, Wu, Guodong, Wang, Youyu, Luo, Weibin, Fang, Fuyuan, Liu, Yuchen, Song, Fei, Cai, Zhiming, Chen, Wei, Huang, Weiren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415928/ https://www.ncbi.nlm.nih.gov/pubmed/32771979 http://dx.doi.org/10.1016/j.isci.2020.101411

Ejemplares similares

Patient-derived organoid (PDO) platforms to facilitate clinical decision making
por: Liu, Lisa, et al.
Publicado: (2021)

Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro
por: Yu, Lei, et al.
Publicado: (2021)

Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer
por: Wan, Yanhui, et al.
Publicado: (2022)

LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival
por: Wan, Yanhui, et al.
Publicado: (2021)

Patient‐derived renal cell carcinoma organoids for personalized cancer therapy
por: Li, Zhichao, et al.
Publicado: (2022)

Protocol for generation of lung adenocarcinoma organoids from clinical samples
por: Li, Zhichao, et al.
Publicado: (2020)

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening
por: Li, Zhichao, et al.
Publicado: (2021)

AB128. Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer
por: Liu, Yuchen, et al.
Publicado: (2016)

AB111. Synthesizing an AND gate genetic circuit for identification of bladder cancer cells based on CRISPR-Cas9
por: Liu, Yuchen, et al.
Publicado: (2014)

Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells
por: Liu, Yuchen, et al.
Publicado: (2020)

Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis
por: Wang, Youyu, et al.
Publicado: (2021)

AB112. Constructing several amiRNAs with multiple targets to silence selectively cancer gene and to inhibit the growth of bladder cancer cells
por: Xin, Fu, et al.
Publicado: (2014)

AB113. BAX apoptosis gene selectively affects bladder cancer cells by artificial hTERT promoter
por: Liu, Yuchen, et al.
Publicado: (2014)

AB127. Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cell
por: Liu, Yuchen, et al.
Publicado: (2016)

Synthesizing artificial devices that redirect cellular information at will
por: Liu, Yuchen, et al.
Publicado: (2018)

Improving transgene expression and CRISPR‐Cas9 efficiency with molecular engineering‐based molecules
por: Zhan, Hengji, et al.
Publicado: (2020)

Recent development on synthetic biological devices treating bladder cancer
por: Chen, Zhicong, et al.
Publicado: (2016)

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
por: Wu, Guodong, et al.
Publicado: (2022)

An Efficient Light-Inducible P53 Expression System for Inhibiting Proliferation of Bladder Cancer Cell
por: Lin, Fan, et al.
Publicado: (2016)

Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy
por: Gong, Miaomiao, et al.
Publicado: (2023)

Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids
por: Wang, Zhiwei, et al.
Publicado: (2021)

Organoid of ovarian cancer: genomic analysis and drug screening
por: Liu, H.-D., et al.
Publicado: (2020)

Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids
por: Wu, Yushuai, et al.
Publicado: (2021)

Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
por: Zhou, Zilong, et al.
Publicado: (2021)

Drug screening model meets cancer organoid technology
por: Liu, Chen, et al.
Publicado: (2020)

Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy
por: Liu, Guangyao, et al.
Publicado: (2022)

Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer
por: Ding, Mengting, et al.
Publicado: (2018)

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening
por: Yuan, Bo, et al.
Publicado: (2022)

Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening
por: Geyer, Marlene, et al.
Publicado: (2021)

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
por: He, Xingfeng, et al.
Publicado: (2023)

A pancreas tumor derived organoid study: from drug screen to precision medicine
por: Yao, Jia, et al.
Publicado: (2021)

Artificial small RNA for sequence specific cleavage of target RNA through RNase III endonuclease Dicer
por: Xu, Wen, et al.
Publicado: (2016)

Identification of Susceptible Genes for Chronic Obstructive Pulmonary Disease with Lung Adenocarcinoma by Weighted Gene Co-Expression Network Analysis
por: Li, Ping, et al.
Publicado: (2021)

Oestrogen promotes tumorigenesis of bladder cancer by inducing the enhancer RNA—eGREB1
por: Ding, Mengting, et al.
Publicado: (2018)

Opportunities and challenges of glioma organoids
por: Xu, Xiangdong, et al.
Publicado: (2021)

The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
por: Low, Ronnie Ren Jie, et al.
Publicado: (2021)

LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression
por: Zhou, Qun, et al.
Publicado: (2019)

Synthetic Tet-inducible artificial microRNAs targeting β-catenin or HIF-1α inhibit malignant phenotypes of bladder cancer cells T24 and 5637
por: Zhan, Yonghao, et al.
Publicado: (2015)

Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells
por: Chen, Zhicong, et al.
Publicado: (2016)

Author Correction: Synthetic Tet-inducible artificial microRNAs targeting β-catenin or HIF-1α inhibit malignant phenotypes of bladder cancer cells T24 and 5637
por: Zhan, Yonghao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i9nhe1qft9jg9lvabsqh2eboso